ARTIST: Translational research in renal cancer (Version 1)
Research type
Research Study
Full title
A translational research Approach to development of optimal Renal cancer Treatments In Surgical and systemic Therapy patients: ARTIST
IRAS ID
258855
Contact name
Sarah W Burge
Contact email
Sponsor organisation
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
Duration of Study in the UK
9 years, 11 months, 30 days
Research summary
Kidney cancer is the 7th most common cancer in the UK and has a poor 5-year survival rate of 56%. Our group has recently shown that the initiating event in kidney cancer may occur as early as the teenage years but little work has examined the progression of kidney cancer from apparently 'normal' kidney through localised kidney cancer (potentially curable by surgery) to metastatic kidney cancer (which is incurable). To improve kidney cancer outcomes, markers identifiable on scans and in blood, urine and/or kidney tissue (so called ‘biomarkers’) are needed a) to identify kidney cancer and its relapse earlier; b) to identify which patients may benefit from additional treatments before/after surgery; and c) to select the best drug treatments to improve survival when kidney cancer spreads. The ARTIST trial will address this by collecting and analysing blood, urine, kidney tissue, stool, imaging data, and relevant clinical information from patients (>16 years of age) at all stages of kidney cancer progression.
Samples from 100 participants recruited each year at Cambridge University Hospitals NHS Foundation Trust, together with retrospective samples/data from appropriately consented participants from previous studies will be examined. Analysis using cutting edge technologies available in Cambridge and from collaborators will characterise kidney cancer and its effects on the body to identify clinically relevant biomarkers. The ARTIST trial will continue for 10 years although each individual patient’s time on the study will be determined by the course of their kidney cancer. ARTIST-specific sampling and assessments will occur at patients’ normal ‘standard of care’ clinical visits and no extra procedures will be needed, although extra blood, urine and/or tissue samples may be collected at the same time as procedures being carried out in the course of normal clinical care, and additional analyses may be performed on scans.
REC name
East of England - Cambridge South Research Ethics Committee
REC reference
20/EE/0200
Date of REC Opinion
26 Oct 2020
REC opinion
Further Information Favourable Opinion